A Top 10 Pharma Company Doubles High-Performing Site Count in a Priority Indication with Medidata AI Intelligent Trials

Case Study

A Top 10 Pharma Company Doubles High-Performing Site Count in a Priority Indication with Medidata AI Intelligent Trials

By Medidata

A Top 10 Pharma Company Doubles High-Performing Site Count in a Priority Indication with Medidata AI Intelligent Trials

By Medidata

Enter your details to receive the free case study:

By downloading this whitepaper, you acknowledge that Progressive Media Investments may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how Progressive Media Investments may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As a top 10 biopharmaceutical company embarked on clinical trials, it wanted to identify new Tier 1 sites and gain insight into the performance of its existing sites.

This in-depth case study explores how Medidata AI integrated cross-industry clinical trial data with the company’s data to more than double its list of high-performing sites.

While reading, you’ll learn more about:
• The challenges the company faced
• The benefits of Medidata AI data compared to publicly available data
• What advantages the company unlocked with Medidata AI

Use Medidata AI’s data to reimagine clinical trial site selection for your business.

A Top 10 Pharma Company Doubles High-Performing Site Count in a Priority Indication with Medidata AI Intelligent Trials

A Top 10 Pharma Company Doubles High-Performing Site Count in a Priority Indication with Medidata AI Intelligent Trials

Changelog